KR20040043182A - 보강제에 의해 증강된 수가와 그렇지 않은 수가의 2 개이상의 수가를 포함하는 백신 조성물 - Google Patents
보강제에 의해 증강된 수가와 그렇지 않은 수가의 2 개이상의 수가를 포함하는 백신 조성물 Download PDFInfo
- Publication number
- KR20040043182A KR20040043182A KR10-2004-7001923A KR20047001923A KR20040043182A KR 20040043182 A KR20040043182 A KR 20040043182A KR 20047001923 A KR20047001923 A KR 20047001923A KR 20040043182 A KR20040043182 A KR 20040043182A
- Authority
- KR
- South Korea
- Prior art keywords
- polysaccharide
- aluminum
- phosphate
- hepatitis
- months
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 229960005486 vaccine Drugs 0.000 title abstract description 30
- 239000002671 adjuvant Substances 0.000 title description 2
- 150000004676 glycans Chemical class 0.000 claims abstract description 30
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 30
- 239000005017 polysaccharide Substances 0.000 claims abstract description 30
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 23
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 20
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 17
- 239000010452 phosphate Substances 0.000 claims abstract description 17
- 238000001179 sorption measurement Methods 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 208000037386 Typhoid Diseases 0.000 claims abstract description 10
- 201000008297 typhoid fever Diseases 0.000 claims abstract description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 6
- 230000001580 bacterial effect Effects 0.000 claims abstract description 6
- 208000005252 hepatitis A Diseases 0.000 claims abstract description 6
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims abstract description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 17
- 230000003053 immunization Effects 0.000 claims description 12
- 238000002649 immunization Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- -1 aluminum compound Chemical class 0.000 claims description 8
- 241000709721 Hepatovirus A Species 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000001681 protective effect Effects 0.000 abstract description 6
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940124929 TYPHIM Vi Drugs 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
5 ℃ | T0 | 3개월 | 6개월 | 9개월 | 12개월 | 18개월 | 24개월 | 30개월 | ||
전체 백신 중의 Vi | Vi ELISA(㎍/용량) | P2 | 23.6 | 25.5 | 21.7 | 21.3 | 18.5 | 23.7 | 24.3 | 26.5 |
P1 | 24.4 | 23.3 | 22.2 | 19.8 | 17.9 | 20.5 | 18.6 | 19.3 | ||
원심분리 후 상등액 중의 Vi | Vi ELISA(㎍/용량) | P2 | 24.3 | 26 | 23.1 | 21.8 | 17.9 | 25 | 21.9 | 25.8 |
P1 | 21 | 16.9 | 16.5 | 15.4 | 12 | 14.7 | 21.8 | 15.7 | ||
O-아세틸(μ몰/용량) | P2 | 0.127 | 0.148 | 0.116 | 0.117 | 0.130 | 0.134 | 0.095 | 0.143 | |
P1 | 0.081 | 0.056 | 0.055 | 0.055 | 0.061 | 0.057 | 0.090 | 0.054 | ||
폴리사카라이드(㎍/용량) | P2 | 32.5 | 30.5 | 27.6 | 31 | 30.4 | 29.1 | 31.7 | 29.3 | |
P1 | 20.8 | 22 | 15.6 | 16.2 | 18.5 | 16.5 | 17 | 18.4 | ||
P1 중의 Vi의 탈착% | 86% | 72% | 74% | 78% | 67% | 72% | 63% | 81.6% |
25 ℃ | T0 | 1개월 | 3개월 | 6개월 | ||
전체 백신 중의 Vi | Vi ELISA(㎍/용량) | P2 | 23.6 | 23.6 | 21.7 | 20.6 |
P1 | 24.4 | 19.6 | 11.3 | 7.4 | ||
원심분리 후 상등액 중의 Vi | Vi ELISA(㎍/용량) | P2 | 24.3 | 25.5 | 22.6 | 20.1 |
P1 | 21 | 15 | 10.3 | 6.3 | ||
O-아세틸(μ몰/용량) | P2 | 0.127 | 0.130 | 0.103 | 0.137 | |
P1 | 0.081 | 0.053 | 0.041 | 0.029 | ||
폴리사카라이드(㎍/용량) | P2 | 32.5 | 31.6 | 25.5 | 27.2 | |
P1 | 20.8 | 17.3 | 10.3 | 6.3 | ||
P1 중의 Vi의 탈착% | 86% | 77% | 91% | 85% |
37 ℃ | T0 | 1개월 | 3개월 | ||
전체 백신 중의 Vi | Vi ELISA(㎍/용량) | P2 | 23.6 | 24.1 | 21 |
P1 | 24.4 | 12.7 | 5.6 | ||
원심분리 후 상등액 중의 Vi | Vi ELISA(㎍/용량) | P2 | 24.3 | 25.5 | 21.1 |
P1 | 21 | 9.9 | 4.7 | ||
O-아세틸(μ몰/용량) | P2 | 0.127 | 0.143 | 0.104 | |
P1 | 0.081 | 0.050 | 0.026 | ||
폴리사카라이드(㎍/용량) | P2 | 32.5 | 36 | 22.5 | |
P1 | 20.8 | 15.4 | 9.9 | ||
P1 중의 Vi의 탈착% | 86% | 78% | 84% |
Claims (8)
- (i) 수산기를 포함하는 알루미늄 화합물에 의해 보강된 제 1 수가, (ii) 하나 이상의 O-아세틸 그룹을 포함하는 세균 캡슐에 든 폴리사카라이드를 함유하는 제 2 수가 및 (iii) 포스페이트, 시트레이트 또는 카보네이트 이온을 포함하는 면역화 조성물.
- 제 1 항에 있어서, 제 1 수가가 A형 간염 수가인 면역화 조성물.
- 제 2 항에 있어서, A형 간염 수가가 불활성화된 A형 간염 바이러스로 이루어진 면역화 조성물.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 제 2 수가가 살모넬라 티피 캡슐에 든 Vi 폴리사카라이드로 이루어진 장티푸스 수가인 면역화 조성물.
- 제 4 항에 있어서, 장티푸스 수가가 24 개월 이상 동안 안정한 항원 역가를갖는 면역화 조성물.
- 제 1 항 내지 제 5 항 중 어느 한 항에 있어서, 제 1 수가가 수산화 알루미늄 또는 알루미늄 하이드록시포스페이트인 알루미늄 화합물에 의해 보강된 조성물.
- 제 1 항 내지 제 6 항 중 어느 한 항에 있어서, 제 1 수가가 알루미늄 화합물 상으로의 흡착에 의해 보강된 조성물.
- (i) 포스페이트, 시트레이트 또는 카보네이트 이온을 수산기를 포함하는 알루미늄 화합물에 의해 보강된 제 1 수가를 함유하는 제제에 가하고;(ii) (i)에서 수득된 제제를 하나 이상의 O-아세틸 그룹을 포함하는 세균 캡슐에 든 폴리사카라이드로 이루어진 제 2 수가를 함유하는 제제와 혼합함에 따른 제 1 항 내지 제 7 항 중 어느 한 항의 면역화 조성물의 제조 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/10,573 | 2001-08-08 | ||
FR0110573A FR2828406B1 (fr) | 2001-08-08 | 2001-08-08 | Composition vaccinale bivalente havi |
PCT/FR2002/002770 WO2003013600A1 (fr) | 2001-08-08 | 2002-07-31 | Composition vaccinale comprenant au moins deux valances, l'une adjuvantee, l'autre pas |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040043182A true KR20040043182A (ko) | 2004-05-22 |
KR100881703B1 KR100881703B1 (ko) | 2009-02-06 |
Family
ID=8866367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047001923A KR100881703B1 (ko) | 2001-08-08 | 2002-07-31 | 항원보강제에 의해 증강된 가(valance)와 그렇지 않은 가(valance)의 2가 이상의 가(valance)를 포함하는 백신 조성물 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7404960B2 (ko) |
EP (1) | EP1416958B2 (ko) |
JP (1) | JP4221291B2 (ko) |
KR (1) | KR100881703B1 (ko) |
CN (1) | CN1282486C (ko) |
AT (1) | ATE357929T1 (ko) |
AU (1) | AU2002342949B2 (ko) |
BR (1) | BRPI0211151B8 (ko) |
CA (1) | CA2455406C (ko) |
CY (1) | CY1107619T1 (ko) |
DE (1) | DE60219177T3 (ko) |
DK (1) | DK1416958T4 (ko) |
ES (1) | ES2284940T5 (ko) |
FR (1) | FR2828406B1 (ko) |
HU (1) | HU228216B1 (ko) |
IL (2) | IL159519A0 (ko) |
MX (1) | MXPA04001125A (ko) |
NZ (1) | NZ530727A (ko) |
PL (1) | PL215134B1 (ko) |
PT (1) | PT1416958E (ko) |
WO (1) | WO2003013600A1 (ko) |
ZA (1) | ZA200400022B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101101901B1 (ko) * | 2009-01-30 | 2012-01-02 | 주식회사 리노 | 주방용 선반 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738682A1 (en) * | 2004-04-15 | 2005-10-15 | Eng-Hong Lee | Soft gel delivery system for treating poultry |
PL2066344T3 (pl) * | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
DK2411048T3 (da) | 2009-03-24 | 2020-06-15 | Glaxosmithkline Biologicals Sa | Adjuvanterende meningokok-faktor h-bindingsprotein |
CN102526724B (zh) * | 2011-01-14 | 2015-07-22 | 四川大学 | 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途 |
FR2985663B1 (fr) | 2012-01-17 | 2015-03-27 | Sanofi Pasteur | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
EP1285666A1 (en) * | 1998-08-28 | 2003-02-26 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Salmonella typhi vaccine compositions |
US6585973B1 (en) * | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
-
2001
- 2001-08-08 FR FR0110573A patent/FR2828406B1/fr not_active Expired - Lifetime
-
2002
- 2002-07-31 CA CA2455406A patent/CA2455406C/en not_active Expired - Lifetime
- 2002-07-31 ES ES02779603T patent/ES2284940T5/es not_active Expired - Lifetime
- 2002-07-31 DE DE60219177T patent/DE60219177T3/de not_active Expired - Lifetime
- 2002-07-31 PL PL367904A patent/PL215134B1/pl unknown
- 2002-07-31 JP JP2003518604A patent/JP4221291B2/ja not_active Expired - Lifetime
- 2002-07-31 HU HU0401182A patent/HU228216B1/hu unknown
- 2002-07-31 BR BR0211151-9 patent/BRPI0211151B8/pt not_active IP Right Cessation
- 2002-07-31 EP EP02779603A patent/EP1416958B2/fr not_active Expired - Lifetime
- 2002-07-31 WO PCT/FR2002/002770 patent/WO2003013600A1/fr active IP Right Grant
- 2002-07-31 US US10/485,748 patent/US7404960B2/en not_active Expired - Lifetime
- 2002-07-31 KR KR1020047001923A patent/KR100881703B1/ko active IP Right Grant
- 2002-07-31 IL IL15951902A patent/IL159519A0/xx unknown
- 2002-07-31 NZ NZ530727A patent/NZ530727A/en not_active IP Right Cessation
- 2002-07-31 AT AT02779603T patent/ATE357929T1/de active
- 2002-07-31 DK DK02779603.6T patent/DK1416958T4/da active
- 2002-07-31 PT PT02779603T patent/PT1416958E/pt unknown
- 2002-07-31 CN CNB028156455A patent/CN1282486C/zh not_active Expired - Lifetime
- 2002-07-31 AU AU2002342949A patent/AU2002342949B2/en not_active Expired
- 2002-07-31 MX MXPA04001125A patent/MXPA04001125A/es active IP Right Grant
-
2003
- 2003-12-22 IL IL159519A patent/IL159519A/en unknown
-
2004
- 2004-01-05 ZA ZA200400022A patent/ZA200400022B/en unknown
-
2007
- 2007-04-16 CY CY20071100521T patent/CY1107619T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101101901B1 (ko) * | 2009-01-30 | 2012-01-02 | 주식회사 리노 | 주방용 선반 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100404312B1 (ko) | 폴리리보실리비톨포스페이트를함유한백신조성물과이들의제조방법 | |
JP6324961B2 (ja) | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン | |
JP2010529103A (ja) | 髄膜炎ワクチンの製剤化 | |
HU227613B1 (en) | Vaccine composition | |
JP2014525429A (ja) | Staphylococcusaureus抗原のアジュバント添加処方物 | |
KR100881703B1 (ko) | 항원보강제에 의해 증강된 가(valance)와 그렇지 않은 가(valance)의 2가 이상의 가(valance)를 포함하는 백신 조성물 | |
Frasch et al. | Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine | |
Vesikari et al. | Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children | |
KR100401423B1 (ko) | 혼합 백신의 제조 방법 | |
JP2015509963A (ja) | Tlr4アゴニストを含む混合ワクチン | |
JP2015509520A (ja) | 狂犬病ウイルス免疫原のアジュバント化製剤 | |
CA2628084A1 (en) | Compositions with antigens adsorbed to calcium phosphate | |
Giammanco et al. | Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
WO2022224966A1 (ja) | 6種混合液状ワクチン組成物 | |
Expósito et al. | Real-time stability of the Ecuadorian pentavalent DTP-HB-Hib vaccine | |
EA040093B1 (ru) | Технология получения вакцины против геморрагической лихорадки с почечным синдромом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130107 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140106 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150106 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180103 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 12 |